TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04308070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUABEAM System followed by catheter without hemostatic agent
Description: The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter to achieve hemostasis post-Aquablation procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AQUABEAM System followed by catheter with hemostatic agent
Description: The AquaBeam system delivers a high-pressure saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The physician will use balloon catheter with hemostatic agent to achieve hemostasis post-Aquablation procedure.
Study: NCT02593162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faldaprevir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-6450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-6450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study: NCT02407262

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Black seed oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vegetable oil
Study: NCT03537144

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: IV indomethacin will be given every 12 hours for 3 doses. If \<48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If \>7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 15mg/kg/dose every 6 hours for 12 doses
Study: NCT00012220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 50 mg/sq m IV infusion over 30 min on Days 1 \& 15 of ea cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 40 mg/sq m IV infusion over 60 min on Days 1 \& 8 of ea treatment cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, \& 15 of ea cycle~* cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle~* docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 \& 8 of ea cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: 100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 \& 8 of ea cycle
Study: NCT03974776

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study: NCT01554644

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prontosan
Description: Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
Study: NCT01888120

Intervention type: DRUG
Intervention: Ziconotide
Study: NCT03778528

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: tissue collection.

Intervention type: PROCEDURE
Intervention: cataract surgery
Description: tissue collection.
Study: NCT00003440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV over 1 hour or 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV over 1 hour or 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV over 1 hour or 3 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV over 1 hour or 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV over 1 hour or 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV over 1 hour or 3 hours

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03662165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: A text was sent three times, one week apart, first in Kiswahili, then in English and then again in Kiswahili, and read: You can now self-test at home or in the clinic for HIV using a new test kit available from all North Star Alliance clinics in Kenya. Your health, our priority. Participants who came to any North Star clinic in Kenya in the intervention arm were given a demonstration of the self-testing kit and then offered a choice among (1) the standard provider-administered blood-based HIV test; (2) the self-administered oral HIV test for use in the clinic with provider supervision; or (3) the self-administered oral HIV test kit for home use with phone-based post-test counseling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Standard of Care
Description: Those randomized to the enhanced Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent three times, one week apart first in Kiswahili, then in English and then again in Kiswahili. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the enhanced SOC arm only offered the standard provider-administered blood-based HIV test.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Standard of Care
Description: Those randomized to the traditional Standard of Care (SOC) arm received the SOC message reminding clients about HIV testing sent one time in both Kiswahili, then in English and Kiswahili simultaneously. The message read: North Star Alliance East Africa would wish to kindly remind you to visit any of our roadside wellness centres for HIV testing. Your health, our priority. Participants who came to any North Star clinic in the traditional SOC arm only offered the standard provider-administered blood-based HIV test.
Study: NCT02181816

Intervention type: DRUG
Intervention: Azilsartan/Amlodipine
Description: Azilsartan/Amlodipine combination tablets LD \& HD
Study: NCT01194713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep deprivation
Description: subjects will undergo one night of full sleep deprivation
Study: NCT00169689

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: rTMS, repetitive transcranial magnetic stimulation
Description: 10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
Study: NCT04187300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Increasing doses of semaglutide administered s.c. (subcutaneouly, under the skin) once weekly for 20 weeks
Study: NCT01612468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 1.8 mg/day subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1.8 mg/day subcutaneous
Study: NCT03182647

Intervention type: PROCEDURE
Intervention: Surgically treatment of the ACL
Description: Surgical initial ACL treatment

Intervention type: OTHER
Intervention: Non surgical initial ACL treatment
Description: Non surgical initial ACL treatment
Study: NCT03268434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: D-MCT
Description: Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation
Description: A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
Study: NCT02219282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Mask Unique insertion
Description: Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Unique insertion
Description: Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
Study: NCT03877562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine 10 mg oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine 10 mg oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CORT118335
Description: CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
Study: NCT00922480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fimasartan
Description: Fimasartan 60 \~ 120mg/po take one tablets once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan (Control)
Description: Losartan 50 mg \~ 100 mg/po, take one tablets once a day
Study: NCT02819635

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Film-coated tablet for oral administration
Study: NCT01687179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus and Hydroxychloroquine 200 mg
Description: This will be a phase I dose escalation study of the combination of Sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and Hydroxychloroquine 200 mg taken orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus and Hydroxychloroquine 400 mg
Description: Once safety is established with the lower dose, (Sirolimus and Hydroxychloroquine 200 mg), subjects will receive Sirolimus 2 mg (adjusted to keep trough levels between 5 to 15 ng/ml) and hydroxychloroquine 200 mg twice a day.
Study: NCT01429818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride/metformin
Description: 4/1000 mg tablets once a day foe eight weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000 mg tablets once daily for eight weeks
Study: NCT02603367

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Undergo communication coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive COMFORT communication curriculum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosocial Support for Caregiver
Description: Undergo communication coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT03687645

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperpolarised MRI
Description: Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperpolarised MRI
Description: Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperpolarised MRI
Description: Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hyperpolarised MRI
Description: Hyperpolarized (HP) 13C MR is an advanced imaging technique that allows monitoring of dynamic metabolic processes non-invasively. Hyperpolarisation is a process that provides dramatic gains in sensitivity (\>10,000) of MRI signal collected from 13C-labelled substrates that can be injected into living systems, allowing in-vivo metabolism for the first time to be observed in real-time using imaging.
Study: NCT02302352

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic 1g once a day by mouth for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
Study: NCT01887067

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation therapy
Study: NCT02428855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Study: NCT00244270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: totally implantable vascular access device
Description: totally implantable vascular access device
Study: NCT01274819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Light
Description: Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
Study: NCT03442036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suture-Method Technique
Description: Perineural catheters are attached to the back of a hollow suture-shaped needle that pulls the catheter adjacent to the target nerve

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Through-the-Needle Technique
Description: Perineural catheters are inserted through a straight hollow-bore needle
Study: NCT01442194

Intervention type: DRUG
Intervention: other disease-modifying therapy

Intervention type: DRUG
Intervention: Fingolimod
Study: NCT04428463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tachosil
Description: tympanic membrane perforation repair using Tachosil patch under local anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fascia and cartilage
Description: tympanic membrane perforation repair using fascia and cartilage under general anesthesia
Study: NCT01788384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate / Benzoyl Peroxide Gel
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle Gel)
Description: Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
Study: NCT03651453

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Participants in the experimental arm will receive the PrEP decision aid.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard harm reduction information
Study: NCT02200354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed with bevacizumab
Study: NCT02999867

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: triticale and mung bean
Description: subjects are assigned to intake of triticale and mung bean for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: adzuki bean
Description: subjects are assigned to intake of adzuki bean for 30 days
Study: NCT03283124

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor reconstructive surgery
Description: transvaginal mesh implantation for pelvic organ prolapse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor reconstructive surgery
Description: transvaginal mesh implantation for pelvic organ prolapse